A comprehensive immunological screening—including complement levels, immunoglobulins, antinuclear antibodies, anti-Sjögren’s syndrome-related antigens (SS-A and SS-B), anti-topoisomerase I (SCL-70), and proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCA)—was conducted by the rheumatology department. The gene discussed is PRTN3; the disease is Sjogren syndrome.